Condition: Severe Burns · Sponsor: Nantes University Hospital
Burns affect more than 11 million people worldwide each year. These injuries are responsible for severe morbidity resulting in a high societal burden and account for more than 180,000 yearly deaths especially in low- and middle-income countries. Major burns induce an important local and systemic inflammatory response that may be overwhelmed. This inflammation is a physiological phenomenon that favours the healing of tissues. However, the overproduction of inflammatory mediators might lead to an exacerbated Systemic Inflammatory Response Syndrome (SIRS). Recently the total body surface area (TBSA) burned has shown to be well correlated to persistent elevation of pro-inflammatory mediators (such as IL-6). This SIRS, in turn, contributes to the enhanced risk of sepsis, acute respiratory distress syndromes (ARDS) and organ failures in general such as acute kidney injuries (AKI), most of those occurring within the first week of admission. Corticosteroids (CS) have already proven their effectiveness against SIRS-induced organ dysfunction or mortality in acute medicine notably in septic shock, polytraumatized patients and more recently in the treatment of viral or non-viral ARDS without increasing the risk of secondary bacterial complications or significant side effects . Indeed the recent SCCM Guidelines clearly advocate for the use of CS in severe community-acquired pneumonia, septic shock and ARDS. The investigators recently performed a large multicenter, double-blinded randomi…
This description comes directly from the study's public registry record.
Karim ASHENOUNE, MD, PhD · +33 (0)2 53 482 835 · karim.asehnoune@chu-nantes.fr
Alexandre BOURDIOL, PH · +33 (0)2 53 482 217 · alexandre.bourdiol@chu-nantes.fr
Always discuss trial participation with your own doctor first.
| CHU Tours | Chambray-lès-Tours, France | Not Yet Recruiting |
| CHU Lille | Lille, France | Not Yet Recruiting |
| CHU de Lyon | Lyon, France | Not Yet Recruiting |
| Aphm Hopital La Timone | Marseille, France | Not Yet Recruiting |
| CHR Metz | Metz, France | Not Yet Recruiting |
| CHU Montpellier | Montpellier, France | Not Yet Recruiting |
| Chu Nantes | Nantes, France | Recruiting |
| HU Saint-Louis Lariboisière | Paris, France | Not Yet Recruiting |
| CHU Bordeaux | Pessac, France | Not Yet Recruiting |
| CHU Toulouse | Toulouse, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06968559